The 17 linked references in paper V. Zimina N., A. Astaf'ev V., В. Зимина Н., А. Астафьев В. (2016) “Внебольничные пневмонии у взрослых больных ВИЧ-инфекцией: особенности течения и лечения, профилактика // Community-acquired pneumonia in adult HIV-infected patients: course, treatment, and prevention” / spz:neicon:pulmonology:y:2016:i:4:p:488-497

  1. Crothers K., Huang L., Goulet J.L. et al. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am. J. Respir. Crit. Care Med. 2011; 183 (3): 388–395. DOI: 10.1164/rccm.2010060836OC.
  2. 1016/j.ijid.2011.05.021. 10. Chew K.W., Yen I.H., Li J.Z. et al. Predictors of pneumonia severity in HIV-infected adults admitted to an Urban public hospital. AIDS Patient Care STDS. 2011; 13 25 (5): 273–277. DOI: 10.1089/apc.2010.0365.
  3. Segal L.N., MethéB.A., Nolan A. et al. HIV-1 and bacterial pneumonia in the era of antiretroviral therapy.Proc. Am. Thorac. Soc.2011; 8 (3): 282–287. DOI: 10.1513/pats. 201006-044WR.
  4. Gordin F.M., Roediger M.P., Girard P.M. et al. Pneumonia in HIV-infected persons: increased risk with cigarette smoking and treatment interruption. Am. J. Respir. Crit. Care Med.2008; 178 (6): 630–636. DOI: 10.1164/rccm.200804617OC.
  5. Bénard A., MerciéP., Alioum A. et al. Bacterial pneumonia among HIV-infected patients: decreased risk after tobacco smoking cessation. ANRS CO3 Aquitaine Cohort, 2000–2007. PLoS One.2010; 5 (1): e8896. DOI: 10.1371/ journal.pone.0008896.
  6. Madeddu G., Fiori L.M., Mura S.M. Bacterial communityacquired pneumonia in HIV-infected patients. Curr. Opin. Pulm. Med.2010; 16 (3): 201–207. DOI: 10.1097/MCP. 0b013e3283375825.
  7. Manno D., Puoti M., Signorini L. et al. Risk factors and clinical characteristics associated with hospitalization for community-acquired bacterial pneumonia in HIV-positive patients according to the presence of liver cirrhosis. Infection. 2009; 37 (4): 334–339. DOI: 10.1007/s15010009-8140-5.
  8. Barry P.M., Zetola N., Keruly J.C. et al. Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990–2003. AIDS. 2006; 20 (3): 437–444 DOI: 10.1097/01.aids.0000206507.54901.84.
  9. Curran A., FalcóV., Crespo M. et al. Bacterial pneumonia in HIV-infected patients: use of the pneumonia severity index and impact of currentmanagement on incidence, aetiology and outcome. HIV Med.2008; 9 (8): 609–615. DOI: 10.1111/j.1468-1293.2008.00603.x.
  10. Horo K., KonéA.,Koffi M.O. et al. Comparative diagnosis of bacterial pneumonia and pulmonary tuberculosis in HIV positive patients. Rev. Mal. Respir.2016; 33 (1): 47–55. DOI: 10.1016/j.rmr.2015.01.004.
  11. Cilloniz C., Torres A., Polverino E. et al.Communityacquired lung respiratory infections in HIV-infected patients: microbial aetiology and outcome.Eur. Respir. J. 2014; 43 (6): 1698–1708. DOI: 10.1183/09031936.00155813.
  12. Porwal C., Kaushik A., Makkar N. et al. Incidence and risk factors for extensively drug-resistant tuberculosis in Delhi region.PLoS One. 2013; 8 (2): e55299. DOI: 10.1371/journal.pone.0055299.
  13. Devasia R.A., Blackman A., Gebretsadik T. et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am. J. Respir. Crit. Care Med. 2009; 180 (4): 365–370. DOI: 10.1164/rccm.200901-0146OC.
  14. Nie W., Li B., Xiu Q. β-Lactam/macrolide dual therapy versus β-lactam monotherapy for the treatment of communityacquired pneumonia in adults: a systematic review and meta-analysis. J. Antimicrob. Chemother. 2014; 69 (6): 1441–1446. DOI: 10.1093/jac/dku033. (the paper at Socionet)
  15. Martin-Loeches I., Lisboa T., Rodriguez A. et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia.Intens. Care Med.2010; 36 (4): 612–620. DOI: 10.1007/s00134-009-1730-y.
  16. Restrepo M.I., Mortensen E.M., Waterer G.W. et al. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur. Respir. J.2009; 33 (1): 153–159. DOI: 10.1183/09031936.00054108.
  17. Sibanda E.L., Weller Ian V.D., Hakim J.G. et al. Does trimethoprim-sulfamethoxazole prophylaxis for HIV induce bacterial resistance to other antibiotic classes? Results of a systematic review. Clin. Infect. Dis.2011; 52 (9): 1184–1194. DOI: 10.1093/cid/cir067.